China and Uruguay Strengthen Strategic Partnership Amid Shifting Global Order 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Federal Judge Blocks Trump Administration Move to End TPS for Haitian Immigrants 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
U.S. Stock Futures Slip as Markets Brace for Big Tech Earnings and Key Data 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Trump Announces U.S.–India Trade Deal Cutting Tariffs, Boosting Markets and Energy Ties 
IMF Forecasts Global Inflation Decline as Growth Remains Resilient 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
South Korea Inflation Hits Five-Month Low as CPI Reaches Central Bank Target 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Fifty-seven lawsuits alleging that hair relaxer products sold by L'Oreal USA Inc and two India-based firms cause cancer and other health problems will be consolidated before US District Judge Mary Rowland in Chicago,
The Chicago federal court will streamline discovery efforts and other pretrial issues for the cases, according to the order.
The lawsuits, which have been filed in federal courts across the country, alleged that the companies knew about the dangerous chemicals in their products but marketed and sold them anyway.
The cases name the US subsidiary of L'Oreal SA and subsidiaries of India-based companies Godrej SON Holdings Inc. and Dabur International Ltd.
Representatives for the companies opposed the centralization of the cases.
L'Oreal said it is confident in the safety of its products and that lawsuits against it have no legal merit.
The claims come in response to a National Institutes of Health research that was published in October and revealed that women who used the products frequently had a greater than doubled risk of developing uterine cancer.
The panel's decision, according to Diandra Debrosse Zimmermann of DiCello Levitt, who filed the initial case after the study's publication, "recognized the clear benefits of centralizing the hair relaxer litigation," and she anticipates that many more companies will do the same in the upcoming weeks.
As the goods are often promoted to women of color, Zimmermann expects hundreds of women may end up suing over them.
